Quetiapine and the Dopaminergic Epigenetic Control
- Registration Number
- NCT00370500
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Brief Summary
BACKGROUND:
Epigenetic modifications such as DNA-methylation and histone acetylation are known to be involved in the pathophysiology of schizophrenia. Aim of the present study is to investigate
1. whether differences in the methylation pattern of the promoters of dopaminergic genes exist between schizophrenic patients and healthy controls and
2. whether treatment with the second generation antipsychotic quetiapine leads to changes in the methylation pattern of those genes in patients suffering from schizophrenia.
STUDY DESIGN AND METHODS:
50 male patients and 50 male controls are to be enrolled into the study. Patients will be treated with quetiapine for 3 weeks. Blood samples will be drawn before treatment and after three weeks to measure DNA-methylation status. Clinical characterisation includes PANSS, AIMS, BDI. Healthy probands will not be treated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A Quetiapine fumarate There is only one arm in this study. All probands receive quetiapine.
- Primary Outcome Measures
Name Time Method Primary variable is the amount of methylated vs. unmethylated promoter specific DNA in the DAT gene of patients before and after treatment with quetiapine (within group comparison). 6 month
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Psychiatry and Psychotherapy, University Erlangen-Nuremberg
🇩🇪Erlangen, Germany